



1-1-2020

Effect of high volume hemodiafiltration on secondary hyperparathyroidism among hemodialysis patients

ahmed alsawy

Internal Medicine department . Faculty of Medicine, Al Azhar University, ahmedelsawy2020@yahoo.com

Follow this and additional works at: <https://aimj.researchcommons.org/journal>



Part of the [Medical Sciences Commons](#), [Obstetrics and Gynecology Commons](#), and the [Surgery Commons](#)

How to Cite This Article

alsawy, ahmed (2020) "Effect of high volume hemodiafiltration on secondary hyperparathyroidism among hemodialysis patients," *Al-Azhar International Medical Journal*: Vol. 1: Iss. 1, Article 14.

DOI: <https://doi.org/10.21608/aimj.2020.21873.1047>

This Original Article is brought to you for free and open access by Al-Azhar International Medical Journal. It has been accepted for inclusion in Al-Azhar International Medical Journal by an authorized editor of Al-Azhar International Medical Journal. For more information, please contact dryasserhelmy@gmail.com.

Effect of High Volume Hemodiafiltration on Secondary Hyperparathyroidism among Hemodialysis Patients

Ezzat A. El Etreby¹MD, Mohamed S. El-Shorbagy²MD, Al-Sayed M. Rashed¹ MD, Ahmed M. Alsawy, MS^{1,*}

*Corresponding Author:

Ahmed Mohamed Alsawy

Ahmedelsawy2020@yahoo.com

Received for publication January 2, 2020; accepted January 18, 2020; Published on line January 24,

Copyright 2020 The Authors published by Al-Azhar University, Faculty of Medicine, Cairo, Egypt. All rights reserved. This an open-access article distributed under the legal terms, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in anyway or used commercially.

doi: 10.21608/aimj.2020.21873.1047

¹Internal Medicine and Nephrology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

²Clinical Pathology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Abstract

Background: Despite increasing knowledge of the uraemic syndrome, both morbidity and mortality remain unacceptably high in patients with chronic kidney disease.

Study investigates the differences between conventional hemodialysis and hemodiafiltration in the context of chronic kidney disease metabolic bone disease findings, serum calcium (sCa), phosphate (sPO₄) and intact parathyroid hormone (PTHint) concentrations.

Patients and methods: This prospective cross over study was approved by Almaadi hospital committee and included 95 patients with CKD5 on regular hemodialysis for at least 6 months. Patients were divided into two groups: Group A: 60 patients scheduled 6 months conventional high flux (hf-HD) (Period1) followed by 6 months of post-dilutional –HDF (Period2).

Group B: (controls) included 35 patients were kept on conventional hf-HD for 12 months. (Period3) for 1st 6 months and (Period4) for 2nd 6 months. The main variables evaluated at the start as well as at the end of each period were sCa, sPO₄ and PTH int.

Results: There was highly significant statistical decrease in Phosphorus level in period2 compared to other groups after 2nd to 6th month and average of overall ($p < 0.001$). A significant statistical decrease was found in Parathormone level and CRP in period2 compared to other groups after 1 month to 6th month and average of overall ($p < 0.05$). There was significant statistical decrease in Albumin level in period2 compared to other groups after 2nd to 6th month and average of overall ($p < 0.05$). There was a significant statistical increase in kt/v in period2 compared to other groups after 1st to 6th month and average of overall ($p < 0.05$).

Conclusion: The switch over from conventional Hf-HD to Ol-HDF results in a significant reduction of both PO₄ and PTH concentrations, no significant changes in Ca concentrations.

Keywords: high volume hemodiafiltration, secondary hyperparathyroidism, Hemodialysis.

Disclosure: The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.
Authorship: All authors have a substantial contributions to the article.

INTRODUCTION

Despite increasing knowledge of the uraemic syndrome, both morbidity and mortality remain unacceptably high in patients with chronic kidney disease. (CKD)¹

Secondary hyperparathyroidism which characterized by increased secretion of parathormone (PTH), is one of the major serious complications in patients with CKD on long-term hemodialysis (HD). Strict control of serum calcium and phosphate concentrations is very important to prevent secondary hyperparathyroidism in those patients.²

Efficient removal of middle-molecular-weight (MMW) uremic toxins is expected to improve patient outcomes in dialysis.³ Convective transport is the main driver for an enhanced clearance of such toxins. Consequently, hemodiafiltration (HDF), a dialysis procedure effectively combining diffusive and convective

transport, has now become the standard dialysis technique in many countries.⁴

MMW substances are not readily cleared by diffusion, which is the main elimination mechanism in low-flux HD.⁵

European Dialysis Working Group (EUDIAL) defined hemodiafiltration as a blood purification therapy combining diffusive and convective solute transport such that the latter is achieved by an effective convection volume of at least 20% of the total blood volume processed. Convection volume is the sum of the substitution fluid volume and the volume of fluid removed during a session (i.e., the difference between the postdialysis and predialysis weights)¹

In modern HDF, fluid balance is maintained by the infusion of 'online' prepared substitution fluid, which can be administered before the dialyser (pre-dilution), midway (mid-dilution) or after the dialyzer. (post-dilution)⁶

Since the vast majority of publications on HDF and clinical outcome concern online post-dilution HDF, this study will focus on this type of treatment. This prospective switchover study investigated the differences between conventional hemodialysis and hemodiafiltration in the context of chronic kidney disease metabolic bone disease (CKD-MBD) findings [serum calcium (sCa), serum phosphate (sPO₄) and intact parathyroid hormone (PTHint) concentrations].

PATIENTS AND METHODS

This cross over study investigated the differences between conventional hemodialysis and hemodiafiltration in the context of CKD-MBD findings stems from the fact that the same patients were examined by two different therapeutic modalities.

This study was approved by Almaadi hospital committee and included 95 patients with CKD5 on regular hemodialysis (HD) in Almaadi Nephrology Unit for at least 6 months prior starting. Study started October, 2018 and patient followed up till October 2019. They were selected after informing consent, full history examination reviewing their medical records and fulfillment the study inclusion and exclusion criteria. They were divided into two groups: Group A included 60 patients scheduled 6 months conventional high flux hemodialysis (hf-HD) (Period 1)) immediately followed by 6 months of post-dilutional -HDF (Period 2). Group B (controls) included 35 patients. They were kept on conventional hf-HD for 12 months. (Period 3) for 1st 6 months and (Period 4) for 2nd 6 months. The main variables evaluated at the start as well as at the end of each period were sCa, sPO₄ and PTHint.

Variables in this study were evaluated both at the start and at the end of each period of observation. They included serum calcium (sCa; mg/dL), serum phosphorus (sPO₄; mg/dL), serum intact parathyroid hormone (PTHint; ng/mL), total serum protein (sProt; g/dL), serum albumin (sAlb; g/dL), plasma sodium (Na; mmol/L), plasma potassium (K; mmol/L), magnesium (Mg; mg/dL), CBC, high sensitive CRP, equilibrated Kt/V (eKt/V), body weight (BW; kg), liver function tests, ECG, pre-dialysis systolic blood pressure (SBP; mmHg) and diastolic blood pressure (DBP; mmHg). All biochemical parameters were drawn before midweek dialysis session to be assayed by their standard methods. Along the study, all patients (95 patients) used ultrapure dialysate as well as the same high flux dialyzer (High flux dialyzer, polysulfone F80 Fresenius Medical Care). Treatment of mineral bone derangement was performed according to the American Kidney Disease Outcome Quality Initiative clinical practice guidelines for bone metabolism and disease in chronic renal failure recommendations. In group A, prescription and dosage changes of the phosphate binders done before the beginning of

period 1 and were kept constant during Period 2. While in group B, changes in the dosage and prescription of phosphate binders' supplementation were allowed according to guidelines. The study included patients above 18 years old on regular HD for at least 6 months and with urinary output below 150 mL/interdialytic. While Patient with active malignancy, chronic infections, decompensated liver cirrhosis, unstable within 3 months before study (myocardial infarction, congestive heart failure, stroke, recent surgery, or severe sepsis), patients who developed hyperphosphatemia were excluded, Vascular access dysfunction (blood flow rate < 300 mL/min) and urinary output more than 150 mL/interdialytic were excluded from the study.

Nephrology

Dialysis prescription

Postdilution HDF was performed using the 5008 CorDiax HDF machine (Fresenius Medical Care, Bad Homburg, Germany). The dialysate solution is bicarbonate for all patients with sodium Na⁺ 140mEq/L, K⁺ 2mEq/L, Ca⁺⁺ 1.75mEq/L, Mg 0.5mEq/L, Cl⁻ 109.5mEq/L, HCO₃ 35mEq/L, CH₃COOH 3mEq/L & the blood pump was kept between 300-400mL/min with dialysate flow 500 mL/min, and heparin sodium as anticoagulant were given 2500 IU as a bolus on initiation of dialysis followed by 500-1000 IU/Hr. All procedures follow Al-Azhar University Ethical committee regulations, and patient consent was taken from all patients.

Statistical Analysis:

Recorded data were analyzed using the statistical package for social sciences, version 20.0 (SPSS Inc., Chicago, Illinois, USA). Quantitative data were expressed as mean ± standard deviation (SD). Qualitative data were expressed as frequency and percentage. **The following tests were done:** Independent-samples t-test of significance was used when comparing between two means. Chi-square (χ^2) test of significance was used in order to compare proportions between qualitative parameters. A one-way analysis of variance (ANOVA) when comparing between more than two means. Post Hoc test: Least Significant Difference (LSD) was used for multiple comparisons between different variables. The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant as the following: Probability (P-value) P-value < 0.05 was considered significant. P-value < 0.001 was considered as highly significant. P-value > 0.05 was considered insignificant. (Figure 1-5) (Table 1, 2)




Fig. 1: Comparison between groups according to Ph. This figure shows statistically significant difference between groups according to Phosphorus (Ph) from after 1 months to Average of overall.




Fig. 2: Comparison between groups according to PTH.

As shown in table (1) and figure (3), there was a statistically significant difference between groups according to Parathormone (PTH) from after 1 months to Average of overall. There is no significant statistical difference between the four groups as regard Parathormone level in the basal ($p > 0.05$), While there is significant

statistical decrease in Parathormone level in period 2 compared to other groups after 1 month to 6th month and average of overall ($p<0.05$).




Fig. 3: Comparison between groups according to Albumin.

This figure shows statistically significant difference between period 2 and overall of the periods according to albumin from after 2 months to Average of overall. There is no significant statistical difference between the four groups as regard Albumin level in the basal and after 1st month ($p>0.05$), While there is significant statistical decrease in Albumin level in period 2 compared to other groups after 2nd to 6th month and average of overall ($p<0.05$).




Fig. 4: Comparison between groups according to CRP.

Figure 4 shows statistically significant difference between period 2 and overall of the periods according to CRP from after 1 months to Average of overall.

Nephrology

There is no significant statistical difference between the four groups as regard CRP in the basal ($p>0.05$), While there is significant statistical decrease in CRP in period 2 compared to other groups after 1st to 6th month and average of overall ($p<0.05$).




Fig. 5: Comparison between groups according to kt/v.

This figure shows statistically significant difference between groups according to kt/v from after 1 months to Average of overall.

There is no significant statistical difference between the four groups as regard kt/v in the basal ($p>0.05$), While there is significant statistical increase in kt/v in period 2 compared to other groups after 1st to 6th month and average of overall ($p<0.05$).

PTH	Group A		Group B		ANOVA	
	Period 1 (n=60)	Period 2 (n=60)	Period 3 (n=35)	Period 4 (n=35)	F	p-value
Baseline line	392.65±176.69	365.77±164.6	370.04±166.52	358.94±161.52	0.109	0.954
After 1 months	392.83±176.78	367.43±165.34a	392.83±176.78b	381.05±171.47b	3.143	0.013*
After 2 months	394.83±177.68	365.57±164.51a	394.83±177.68b	382.99±172.34b	3.426	0.012*
After 3 months	395.52±177.98	364.00±163.8a	395.52±177.98b	383.65±172.64b	3.734	0.010*
After 4 months	396.58±178.46	364.71±164.12a	396.58±178.46b	384.69±173.11b	3.585	0.009*
After 5 months	372.83±253.28	364.71±164.12a	382.83±253.28ab	371.95±145.68b	2.814	0.024*
After 6 months	374.32±168.44	360.15±131.3a	374.32±168.44b	367.09±163.39b	3.304	0.012*
Average of overall	415.65±187.04	365.42±164.44a	412.42±185.59b	400.05±180.02b	3.172	0.014*

Table 1: Comparison between groups according to Parathormone.

CRP	Group A		Group B		ANOVA	
	Period 1 (n=60)	Period 2 (n=60)	Period 3 (n=35)	Period 4 (n=35)	F	p-value
Baseline line	10.4±4.37	10.4±4.37	9.8±4.12	9.8±4.12	0.188	0.905
After 1 months	10.47±4.4	9.11±3.83a	10.6±4.45b	10.51±4.42b	2.801	0.042*
After 2 months	10.43±4.38	9.07±3.81a	10.43±4.38b	10.8±4.54b	2.320	0.044*
After 3 months	10.52±4.42	9.15±3.85a	10.29±4.32b	10.29±4.32b	4.242	0.008*
After 4 months	10.41±4.37	9.06±3.80a	10.66±4.48b	10.23±4.3b	3.711	0.033*
After 5 months	10.45±5.06	8.74±4.40a	10.26±4.31b	10.14±4.26b	2.779	0.014*
After 6 months	10.4±4.37	9.05±3.80a	10.34±4.34b	9.86±4.14b	2.629	0.037*
Average of overall	10.66±4.48	9.27±3.90a	10.34±4.34b	10.23±4.3b	3.025	0.036*

Table 2: Comparison between groups according to C reactive Protei

DISCUSSION

Hemodiafiltration (HDF) is a newer technique of dialysis that achieves clearance of middle and large molecular weight solutes unlike conventional hemodialysis (HD). HD is based on the diffusive transport of solutes across a semipermeable membrane and is effective in removing small solutes only, whereas HDF also involves the infusion of sterile, pyrogen-free fluid either pre- or post-filter and thereby allows clearance by convection as well as diffusion.⁷

Our study was conducted on 95 chronic hemodialysis patients on regular hemodialysis (HD). They were divided into four groups: Group A included 60 patients scheduled 6 months conventional high flux (hf-HD) (Period 1) immediately followed by 6 months of post-dilutional -HDF (Period 2). Group B (controls) included 35 patients. They were kept on conventional hf-HD for 12 months. (Period 3) for 1st 6 months and (Period 4) for 2nd 6 months.

In group A: 30 of them were females (50%), 30 of them were males (50%).

Anemia is a major comorbidity of patients with end-stage renal disease and poses an enormous economic burden to health-care systems. High dose erythropoiesis-stimulating agents (ESAs) have been associated with unfavorable clinical outcomes.⁸

In our study There is no significant statistical difference between the four groups as regard Hemoglobin level in the basal ($p>0.05$). While there is significant statistical increase in Hemoglobin level in period 2 compared to other groups after the 1st, 2nd, 3rd, 4th, 5th month and average of overall ($p<0.05$) and highly significant statistical increase in Hemoglobin level in period 2 compared to other groups after the 6th month ($p<0.001$), which agree with the study done by ⁹ and ¹⁰; but this result disagree with the study done by ¹¹ and ¹² which showed no change in Hemoglobin level.

Phosphorus is found in plasma in a variety of compounds, such as pyrophosphates, decametaphosphates or phosphates bound to proteins. These forms of phosphorus have higher molecular weights and lower diffusion rates, so that their removal can be only improved by adding convective clearance.¹³

There is no significant statistical difference between the four groups as regard Phosphorus level in the basal ($p>0.05$)). While there is significant statistical decrease in Phosphorus level in period 2 compared to other groups after the 1st month ($p<0.05$) and highly significant statistical decrease in Phosphorus level in period 2 compared to other groups after 2nd, 3rd, 4th, 5th, 6th month and average of overall ($p<0.001$); which agree with the study done by ¹¹.but this result disagree with the study done by ¹⁴ in which Phosphate levels were higher in patients who were on HDF compared with high-flux HD. High serum PTH levels in ESKD have been related to a poor clinical outcome.¹⁵

There is no significant statistical difference between the four groups as regard Parathormone level in the basal ($p>0.05$)). While there is significant statistical decrease in Parathormone level in period 2 compared to other groups after 1 month to 6th month and average of overall ($p<0.05$); which agree with the study done by ¹¹; but this result disagree with the study done by ¹² in which there are any changes in serum levels of PTH. Albumin loss during online HDF treatment is dependent both on

the filtration volume and the type of membrane was recently confirmed in a controlled study, which however only assessed albumin loss during the first hour of treatment.¹⁶

The clinical relevance of some extra albumin loss during post dilution online HDF, however, is uncertain ¹⁷ did not observe a relation between albumin loss and nutritional parameters.

There is no significant statistical difference between the four groups as regard Albumin level in the basal and after 1st month ($p>0.05$)). While there is significant statistical decrease in Albumin level in period 2 compared to other groups after 2nd to 6th month and average of overall ($p<0.05$); which agree with the study done by ¹², but this result disagree with the study done by ¹⁸ in which Mean serum albumin was not significantly different between patients who were treated predominantly with HDF or high-flux HD.

Systemic inflammation is commonly observed in patients with chronic kidney disease and has been shown to have a role in the development and progression of cardiovascular disease (CVD) and to predict mortality in end-stage kidney disease ¹⁸.

Online hemodiafiltration (ol HDF) may decrease inflammatory activity through enhanced clearance of middle molecules by convection; on the other hand, the infusion of large amounts of substitution fluid may induce inflammatory activity when water is contaminated. However, the potential risk of contamination is very low as we and others previously showed by analyzing a large amount of samples of dialysis fluids.¹⁹

There is no significant statistical difference between the four groups as regard CRP in the basal ($p>0.05$)). While there is significant statistical decrease in CRP in period 2 compared to other groups after 1st to 6th month and average of overall ($p<0.05$). This result agrees with the study done by ²⁰ and ⁹ and this result disagrees with the study done by ²¹ and ²², in which there was no difference in the C-reactive protein ratios comparing HD vs. Ol-HDF treatments.

There is no significant statistical difference between the four groups as regard kt/v in the basal ($p>0.05$)). While there is significant statistical increase in kt/v in period 2 compared to other groups after 1st to 6th month and average of overall ($p<0.05$). This result agrees with the study done by ²³ and this result disagrees with the study done by ¹¹ and ¹⁴, in which there are similar kt/v in both groups Online Hemodiafiltration and High-Flux Hemodialysis.

CONCLUSION

In conclusion, in this study, the switch over from conventional Hf-HD to Ol-HDF results in a significant reduction of both PO₄ and PTH concentrations, no significant changes in Ca concentrations. This supports the idea that Ol-HDF could be of help in controlling the uraemic mineral metabolism derangement in dialysis patients. Online hemodiafiltration (HDF) may decrease inflammatory activity. Hemoglobin level and kt/v were higher in patients who were treated with Ol-HDF. Loss of albumin was higher in the Ol-HDF group.

REFERENCES

1. Tattersall J and Ward R. Online haemodiafiltration: definition, dose quantification and safety revisited. *Nephrol Dial Transplant*. 2013; 28:542–50.
2. Locatelli F and Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease

- progression, and therapeutic options. *Clin J Am Soc Nephrol.*; 2011 6(4):913–21.
3. Lornoy W, Becaus I, Billioux JM, et al. On-line haemodiafiltration: remarkable removal of β_2 -microglobulin. Long-term clinical observations. *Nephrol Dial Transplant.* 2000; 15 (1):49–54.
4. Marcelli D, Scholz C, Ponce P, et al. (2015): High-Volume Postdilution Hemodiafiltration Is a Feasible Option in Routine Clinical Practice. *Artificial Organs.* 2015; 39(2):142–149.
5. Ledebro I and Blankestijn P. Haemodiafiltration-optimal efficiency and safety. *NDT Plus* 2010; 3: 8–16.
6. Mostovaya M, Muriel P, Grooteman, et al. High convection volume in online post-dilution haemodiafiltration: relevance, safety and costs *Clinical Kidney Journal.* 2015; 8(4): 368–373.
7. Leurs P, Lindholm B, Stenvinkel P (2013). Effects of hemodiafiltration on uremic inflammation. *Blood Purif.* 35 Suppl 1:11–7. doi: 10.1159/000346359.
8. Luciano A, Adam M, Anke C. et al. Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients. Available on line: <https://doi.org/10.1371/journal.pone.0212795>. Accessed November 22, 2019.
9. Maduell F, Javier Varas, Rosa Ramos, et al. Hemodiafiltration Reduces All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients: A Propensity-Matched Cohort Study. *Am J Nephrol.* 2017; 46:288–297.
10. Locatelli F, Altieri P, Andrulli S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. *J Am Soc Nephrol.* 2010; 21:1798–1807.
11. Ezio Movilli, Corrado Camerini, Paola Gaggia, et al. Effect of post-dilutional on-line haemodiafiltration on serum calcium phosphate and parathyroid hormone concentrations in uraemic patients. *Nephrol Dial Transplant.* 2011; 26: 4032–4037.
12. Guillaume Jean, Jean-Marc Hurot, Patrik Deleaval, et al. haemodiafiltration vs. conventional haemodialysis: a cross-over study. Jean, et al. *BMC Nephrology* 2015; 7; 16:70.
13. Davenport A, Gardner C, Delaney M; Pan Thames Renal Audit Group. The effect of dialysis modality on phosphate control: haemo-dialysis compared to haemodiafiltration. The Pan Thames Renal Audit. *Nephrol Dial Transplan.* 2010; 25: 897–901.
14. Vilar E, Fry AC, Wellsted D, et al. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. *Clin J Am Soc Nephrol.* 2009; 4:1944–53.
15. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. *Kidney Int.* 2008; 73(11):1296–302.
16. Vega A, Quiroga B, Abad S, et al. Albumin leakage in online hemodiafiltration, more convective transport, more losses? *Ther Apher Dial.* 2015; 19(3):267–71.
17. Fournier A, Birmele B, Francois M, et al. Factors associated with albumin loss in post-dilution hemodiafiltration and nutritional consequences. *Int J Artif Organs.* 2015; 38(2):76–82.
18. Bazeley J, Bieber B, Li Y, et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. *Clin J Am Soc Nephrol.* 2015; 6: 2452–2461.
19. Penne EL, Visser L, van den Dorpel MA, et al. Microbiological quality and quality control of purified water and ultrapure dialysis fluids for online hemodiafiltration in routine clinical practice. *Kidney Int.* 2009; 76: 665–672.
20. Claire H. den Hoedt, Michiel L. Bots, Muriel P.C. Grooteman. Hemo-diafiltration reduces systemic inflammation compared to low-flux hemodialysis 2014. Available on line at: [https://www.kidney-international.org/article/S0085-2538\(15\)30278-7/abstract](https://www.kidney-international.org/article/S0085-2538(15)30278-7/abstract) Accessed december 1, 2019.
21. Jia P, Jin W, Teng J, et al. Acute Effects of Hemodiafiltration versus Conventional Hemodialysis on Endothelial Function and Inflammation: A Randomized Crossover Study. *Medicine* (Baltimore). 2016;95(16):e3440.doi:10.1097/MD.0000000000003440
22. Grit Waitz, Jürgen Bock, Peter Ahrenholz, et al. Albumin/ C-reactive protein ratio in the treatment of patients with chronic kidney disease - high flux hemodialysis vs. online hemodiafiltration. *Nephrology Dialysis Transplantation*, Volume 33, Issue suppl_1, May 2018, Page i192, <https://doi.org/10.1093/ndt/gfy104.FP463>
23. Locatelli F, Karaboyas A, Pisoni RL, et al. Mortality risk in patients on hemodiafiltration versus hemodialysis: a ‘realworld’ comparison from the DOPPS. *Nephrol Dial Transplant* 2018; 33:683–689.